Information  X 
Enter a valid email address

Proteome Sciences (PRM)


Wednesday 05 May, 2021

Proteome Sciences

Result of AGM

RNS Number : 6469X
Proteome Sciences PLC
05 May 2021

5 May 2021







Proteome Sciences plc

("Proteome Sciences" or the "Company")


Result of Annual General Meeting (AGM)


The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 11.00 a.m. today, all resolutions were duly passed.





For further information:


Proteome Sciences plc

Dr Mariola Soehngen, Chief Executive Officer &

Dr Ian Pike, Chief Scientific Officer



Tel: +44 (0)20 7043 2116


Allenby Capital Limited (AIM Nominated Adviser & Broker) 

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656



About Proteome Sciences plc. ( )


Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.


The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t